NVS vs PTCT: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: NVS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NVS and PTCT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NVS and PTCT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. Over the past several years it deliberately reshaped itself into a pure-play innovative-medicines business: it spun off the Alcon eye-care division in 2019 and separated the Sandoz generics and biosimilars unit in 2023, distributing those shares to Novartis holders. What remains is a focused portfolio of patented prescription drugs concentrated in four therapeutic areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic disease. Oncology is its largest contributor, and the company has built a reputation for high core operating margins, reaching roughly 40% in 2025. Revenue was about $56.7 billion in 2025, roughly 10% above 2024, and trailing twelve-month revenue is at about the same level with net income near $12.8 billion.

Full NVS guide

PTC Therapeutics is a New Jersey-based biopharmaceutical company focused on rare and neurological diseases. It sells a portfolio of approved medicines including Sephience (sepiapterin) for phenylketonuria (PKU), Translarna (ataluren) and Emflaza (deflazacort) for Duchenne muscular dystrophy, and Kebilidi, a gene therapy for AADC deficiency. It also earns royalties on Evrysdi (risdiplam), the Roche/Genentech spinal muscular atrophy drug that PTC helped discover, and runs a pipeline led by votoplam, a splicing modifier partnered with Novartis for Huntington's disease. In September 2026 it completed the acquisition of ST-920 (isaralgagene civaparvovec), a one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics.

Full PTCT guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• NVS drivers: Priority growth brands offsetting the cliff; Focused, high-margin innovative-medicines model.
• PTCT drivers: Sephience (PKU) launch ramp; Evrysdi royalty and cash generation.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed. For PTCT, the largest risk is legacy-franchise erosion: Translarna is sold in Europe without a valid marketing authorization and faces removal, while Emflaza has lost exclusivity, so a meaningful revenue base could disappear.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick NVS if you believe its drivers more; PTCT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NVS and PTCT guides.

NVS. At about $151, NVS trades near 23 times trailing earnings but only about 15 times forward estimates, a gap that reflects reported profit depressed by the Entresto cliff and an expected rebound to about $9.80 of EPS in 2027. The analyst mean target of roughly $155 sits close to the current price, so the October 27 third-quarter report and how fast the growth brands keep absorbing the generic erosion matter more than any single trailing figure. Figures are approximate and tied to the asOf date; verify live numbers before acting.

PTCT. PTCT trades at about 5x trailing revenue and roughly 25x forward earnings, typical for a rare-disease specialist that has only just turned profitable on a quarterly basis. Because much of the near-term growth rides on the Sephience launch curve, the valuation is sensitive to launch trajectory and legacy-revenue durability rather than a simple earnings multiple. The heavy royalty-monetization liabilities and about $3.0 billion of debt mean enterprise value differs materially from market cap, and the gap between the roughly $60 share price and an average analyst target near $100 shows how divided views are ahead of Q3 results on October 29, 2026.

Headline figures (approximate, October 2026): NVS shows revenue (ttm) ~$56.7B; Q2 2026 revenue ~$14.95B, up ~1% year over year, growth drivers Priority brands Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix offsetting Entresto's generic decline, margins (ttm) ~75% gross, ~35% operating, ~22.5% net, net income (ttm) ~$12.8B; PTCT shows market cap ~$5.0 billion (stock ~$59.92, down ~22% YTD), revenue (ttm) ~$1.01 billion, q2 2026 revenue ~$361 million (roughly double year over year), q2 2026 eps ~$0.92 vs ~$0.34 consensus.

NVS and PTCT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined NVS and PTCT exposure against your real portfolio. It is not an investment adviser.